{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:18:12Z","timestamp":1791235092744,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtha.2025.02.025","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T12:36:24Z","timestamp":1741264584000},"page":"1464-1468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Anticoagulant drugs targeting factor XI\/XIa and coagulation tests: we urgently need reliable pharmacodynamic data"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-9005","authenticated-orcid":false,"given":"Isabelle","family":"Gouin-Thibault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3269-6156","authenticated-orcid":false,"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lasne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.02.025_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.02.025_bib2","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: moving beyond factor Xa inhibitors","volume":"21","author":"Fredenburgh","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib3","first-page":"69","article-title":"Development of new anticoagulant in 2023: prime time for anti-factor XI and XIa inhibitors","volume":"48","author":"Bentounes","year":"2023","journal-title":"J\u00a0Med Vasc"},{"key":"10.1016\/j.jtha.2025.02.025_bib4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib5","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"22","author":"Levy","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ijlh.13196","article-title":"The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays","volume":"42","author":"Exner","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.025_bib7","first-page":"6314","article-title":"Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders","volume":"11","author":"Campello","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2025.02.025_bib8","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/diagnostics14171991","article-title":"Laboratory evaluation of interferences associated with factor XIa inhibitors asundexian and milvexian in routine coagulation assays","volume":"14","author":"Buckley","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtha.2025.02.025_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2017.12.023","article-title":"Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency","volume":"163","author":"Salloum-Asfar","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.025_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In\u00a0vitro studies and in\u00a0vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.025_bib12","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2025.02.025_bib14","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Brit J Clinical Pharma"},{"key":"10.1016\/j.jtha.2025.02.025_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.025_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ijlh.14002","article-title":"How to assess parallelism in factor assays: coefficient of variation of results with different dilutions or slope ratio?","volume":"45","author":"Guy","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.025_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.025_bib20","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.02.025_bib22","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric Inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jtha.2025.02.025_bib23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","article-title":"Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure?","volume":"236","author":"Vassart","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.025_bib24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2516.2010.02246.x","article-title":"Thrombin generation in patients with factor XI deficiency and clinical bleeding risk","volume":"16","author":"Rugeri","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.02.025_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/hae.14506","article-title":"Report of surgeries, their outcome and the thrombin generation assay in patients with factor XI deficiency: a retrospective single-centre study","volume":"28","author":"D\u00e9sage","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.02.025_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-0040-1715899","article-title":"Tissue factor-independent coagulation correlates with clinical phenotype in factor XI deficiency and replacement therapy","volume":"121","author":"Bertaggia Calderara","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2014-12-616565","article-title":"Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency","volume":"126","author":"Pike","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.025_bib28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jtha.2023.10.009","article-title":"Reversal of factor XI targeting anticoagulants: an in\u00a0vitro evaluation","volume":"22","author":"Bakhtiari","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.025_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:36:36Z","timestamp":1777638996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1538783625001242"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.025","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulant drugs targeting factor XI\/XIa and coagulation tests: we urgently need reliable pharmacodynamic data","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}